The Science Behind Abagen®

Abagen’s anti-inflammatory properties are rooted in protein-rich extracts derived from blacklip abalone (Haliotis rubra). Detailed in patent WO 2017/124149 and reinforced by peer-reviewed studies (Suleria et al., 2017), this peptide, developed by Southern Ocean Biotech, has been rigorously tested in both in vitro and in vivo models, demonstrating its potential as a therapeutic agent for IL-6 mediated inflammatory conditions, including rheumatoid arthritis.

In Vitro Findings

In laboratory studies using LPS-stimulated RAW 264.7 murine macrophages, Abagen® extracts significantly reduced nitric oxide (NO) production—a hallmark of inflammation—by 40-80%. Sample 2-2 achieved a 79% reduction at 52.7 µg/mL collagen concentration, outperforming the positive control quercetin (70% reduction at 10 µM) (Patent WO 2017/124149, Table 2, Figure 1). These results confirm Abagen’s potent anti-inflammatory activity at a cellular level, aligning with findings from Suleria et al. (2017) that highlight abalone-derived extracts’ bioactive potential.

In Vivo Evidence

A collagen-induced arthritis (CIA) mouse model of rheumatoid arthritis validated Abagen’s efficacy. When administered prophylactically or therapeutically at doses of 100-500 mg/kg/day, Abagen® reduced clinical arthritis scores by up to 50% (p<0.0001), decreased joint synovitis (p<0.01), and lowered circulating IL-6 levels (p<0.01) compared to controls (Patent WO 2017/124149, Figures 6-11). These outcomes, showing reduced swelling, deformity, and inflammation, position Abagen® as a promising candidate for chronic inflammatory disease management. Suleria et al. (2017) further corroborate abalone’s therapeutic potential, noting its bioactive consistency across studies.

Mechanism of Action

Abagen’s protein-enriched fractions target IL-6 mediated pathways, a critical driver of chronic inflammation in diseases like rheumatoid arthritis. By inhibiting nitric oxide production and reducing IL-6 levels, Abagen disrupts the inflammatory cascade, offering a natural alternative to synthetic IL-6 inhibitors. Its bioactive components, primarily proteins such as collagen, are isolated through enzymatic digestion and fractionation processes detailed in the patent and supported by Suleria et al. (2017).

Research Highlights

  • Nitric Oxide Reduction: Up to 79% decrease in vitro, surpassing industry standards (Patent WO 2017/124149, Figure 1; Suleria et al., 2017).

  • Clinical Score Improvement: Up to 50% reduction in arthritis severity in vivo (Patent WO 2017/124149, Figure 8).

  • IL-6 Suppression: Significant decrease in circulating IL-6, a key inflammatory cytokine (Patent WO 2017/124149, Figure 9).

  • Consistency Across Studies: Anti-inflammatory effects validated in multiple abalone-derived extracts (Suleria et al., 2017).

Be the First to Discover Abagen®

Subscribe for exclusive updates!
Get early access to information about Abagen®